What is the role of dependence-related behavior in medication-overuse headache?

Headache

Volumn 50, Issue 10, 2010, Pages 1597-1611

  Radat, Françoise ^a   Lanteri Minet, Michel ^b  

^a HÔPITAL PELLEGRIN   (France)

^b PASTEUR HOSPITAL   (France)

Author keywords

behavior; dependence; medication overuse headache; substance related disorder; therapeutic management

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; CAFFEINE; CODEINE; CORTICOTROPIN RELEASING FACTOR; ENDOCANNABINOID; ERGOT DERIVATIVE; FLUORODEOXYGLUCOSE F 18; IBUPROFEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OREXIN; PARACETAMOL; RIZATRIPTAN; SEDATIVE AGENT; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ALCOHOL CONSUMPTION; ANALGESIA; BEHAVIOR; BORDERLINE STATE; CINGULATE GYRUS; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; COMORBIDITY; CORPUS STRIATUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DEPENDENCE; DRUG INDUCED HEADACHE; GENETIC PREDISPOSITION; HELPLESSNESS; HUMAN; INSULA; MOOD DISORDER; NEUROIMAGING; ORBITAL CORTEX; PARIETAL LOBE; PATHOPHYSIOLOGY; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL ASPECT; PUNISHMENT; QUESTIONNAIRE; RELAPSE; RELAXATION TRAINING; REVIEW; REWARD; RISK FACTOR; SMOKING; THALAMUS; TOBACCO; TRANSFORMED MIGRAINE;

HEADACHE DISORDERS, SECONDARY; HUMANS; SUBSTANCE-RELATED DISORDERS; TERMINOLOGY AS TOPIC;

EID: 78649261550     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01755.x     Document Type: Review

References (85)

1. Dreisbach RH,. Experimental caffeine withdrawal headache. J Pharmacol Exp Ther. 1940; 69: 283.
2. Mathew NT, Stubits E, Nigam MP,. Transformation of episodic migraine into daily headache: Analysis of factors. Headache. 1982; 22: 66-68.
3. Diener HC, Limmroth V,. Medication-overuse headache: A worldwide problem. Lancet Neurol. 2004; 3: 475-483.
4. Limmroth V, Katsarava Z,. Medication overuse headache. Curr Opin Neurol. 2004; 17: 301-306.
5. Castillo J, Muñoz P, Guitera V, Pascual J,. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999; 39: 190-196.
6. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: Prevalence, risk factors, and biannual follow-up. Neurology. 2000; 54: 314-319.
7. Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ,. Chronic daily headache in Taipei, Taiwan: Prevalence, follow-up and outcome predictors. Cephalalgia. 2001; 21: 980-986.
8. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J,. Chronic daily headache with analgesic overuse: Epidemiology and impact on quality of life. Neurology. 2004; 62: 1338-1342.
9. Zwart JA, Dyb G, Hagen K, Svebak S, Stovner LJ, Holmen J,. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004; 62: 1540-1544.
10. Granella F, Farina S, Malferrari G, Manzoni GC,. Drug abuse in chronic headache: A clinico-epidemiologic study. Cephalalgia. 1987; 7: 15-19.
11. Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: Data from a physician survey. Headache. 1996; 36: 14-19.
12. Calabresi P, Cupini LM,. Medication-overuse headache: Similarities with drug addiction. Trends Pharmacol Sci. 2005; 26: 62-68.
13. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
14. Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005; 25: 460-465.
15. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
16. Dodick DW,. Analgesic overuse is not a cause of chronic daily headache. Headache. 2002; 42: 547-554.
17. Tepper SJ,. Analgesic overuse is a cause of chronic daily headache. Headache. 2002; 42: 543-547.
18. Lipton RB, Bigal ME,. Chronic daily headache: Is analgesic overuse a cause or a consequence? Neurology. 2003; 61: 154-155.
19. Mathew NT,. Medication misuse headache. Cephalalgia. 1998; 18 (Suppl. 21): 34-36.
20. Scher AI, Stewart WF, Liberman J, Lipton RB,. Prevalence of frequent headache in a population sample. Headache. 1998; 38: 497-506.
21. Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB,. Chronic daily headache: Identification factors associated with induction and transformation. Headache. 2002; 42: 575-581.
22. Denisco RA, Chandler RK, Compton WM,. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol. 2008; 16: 417-428.
23. Pascual J, Colás R, Castillo J,. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001; 5: 529-536.
24. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB,. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24: 483-490.
25. Radat F, Creac'h C, Guegan-Massardier E, et al. Behavioral dependence in patients with medication overuse headache: A cross-sectional study in consulting patients using the DSM-IV criteria. Headache. 2008; 48: 1026-1036.
26. Grande RB, Aaseth K, Åaltyte-Benth J, Gulbrandsen P, Russell MB, Lundqvist C,. The severity of dependence scale detects people with medication overuse. The Akershus study of chronic headache. J Neurol Neurosurg Psychiatry. 2009; 80: 784-789.
27. Dodick D, Freitag F,. Evidence-based understanding of medication-overuse headache: Clinical implications. Headache. 2006; 46 (Suppl. 4): 202-211.
28. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB,. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008; 48: 1157-1168.
29. Scher AI, Lipton RB, Stewart WF, Bigal M,. Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study. Cephalalgia. 2009 Jul 10. [Epub ahead of print].
30. Schoenen J, Lenarduzzi P, Sianard-Gainko J,. Chronic headaches associated with analgesics and/or ergotamine abuse: A clinical survey of 434 consecutive outpatients. In:, Rose FC, ed. New Advances in Headache Research. London: Smith-Gordon & Co Ltd; 1989: 255-259.
31. Bahra A, Walsh M, Menon S, Goadsby PJ,. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003; 43: 179-190.
32. Schnider P, Aull S, Baumgartner C, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: Five-year follow-up. Cephalalgia. 1996; 16: 481-485.
33. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G,. Rates and predictors for relapse in medication overuse headache: A 1-year prospective study. Neurology. 2003; 60: 1682-1683.
34. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V,. Medication overuse headache: Rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005; 25: 12-15.
35. Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007; 27: 1219-1225.
36. Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A,. Analgesic-induced chronic headache: Long-term results of withdrawal therapy. J Neurol. 1989; 236: 9-14.
37. Pini LA, Bigarelli M, Vitale G, Sternieri E,. Headaches associated with chronic use of analgesics: A therapeutic approach. Headache. 1996; 36: 433-439.
38. Suhr B, Evers S, Bauer B, Gralow I, Grotemeyer KH, Husstedt IW,. Drug-induced headache: Long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia. 1999; 19: 44-49.
39. Pini LA, Cicero AFG, Sandrini M,. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia. 2001; 21: 878-883.
40. Goodman A,. Addiction: Definition and implications. Br J Addict. 1990; 85: 1403-1408.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington, VA: American Psychiatric Publishing Inc; 1994.
42. Fischer B, Patra J, Cruz MF, Gittins J, Rehm J,. Comparing heroin users and prescription opioid users in a Canadian multi-site population of illicit opioid users. Drug Alcohol Rev. 2008; 31: 1-8.
43. Drucker E,. Injectable heroin substitution treatment for opioids dependency. Lancet. 2001; 358: 1385.
44. Saunders JB, Schuckit MA, Sirovatka MS, Rogiier DA,. Diagnostic Issues in Substance Use Disorders. Refining the Research Agenda for DSM V. Arlington, VA: American Psychiatric Publishing Inc; 2007.
45. Degenhardt L, Hall W, Lynskey M,. Exploring the association between cannabis use and depression. Addiction. 2003; 98: 1493-1504.
46. Weissman DE, Haddox JD,. Opioid pseudoaddiction-an iatrogenic syndrome. Pain. 1989; 36: 363-366.
47. American Pain Society. Definitions related to the use of opioids for the treatment of pain. 2007. Available at: www.ampainsoc.org/advocacy/opiod2.htm (Accessed January 21, 2008).
48. Nicholson B, Passik SD,. Management of chronic noncancer pain in the primary care setting. South Med J. 2007; 100: 1028-1036.
49. Bell K, Salmon A,. Pain, physical dependence and pseudoaddiction: Redefining addiction for "nice" people? Int J Drug Policy. 2009; 20: 170-178.
50. Haag G,. LDQ-validated for headache diseases? Published Online: June 1, 2009.
51. Ferrari A, Cicero AFG, Bertolini A, Leone S, Pasciullo G, Sternieri E,. Need for analgesics/drugs of abuse: A comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia. 2005; 26: 187-193.
52. Radat F, Irachabal S, Lafittau M, Creac'h C, Dousset V, Henry P,. Construction of a medication dependence questionnaire in headache patients (MDQ-H) validation of the French version. Headache. 2006; 46: 233-239.
53. Fuh JL, Wang SJ, Lu SR, Juang KD,. Does medication overuse headache represent a behavior of dependence? Pain. 2005; 119: 49-55.
54. Fishbain DA, Rosomoff HL, Rosomoff RS,. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992; 8: 77-85.
55. Radat F, Creac'h C, Swendsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia. 2005; 25: 519-522.
56. Straube A, Pfaffenrath V, Ladwig K-H, et al. Prevalence of chronic migraine and medication overuse headache in Germany-The German DMKG headache study. Cephalalgia. Published Online: June 1, 2009.
57. Cevoli S, Sancisi E, Grimaldi D, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009; 49: 412-418.
58. Sances G, Ghiotto N, Galli F, et al. Risk factors in medication-overuse headache: A 1-year follow-up study (care II protocol). Cephalalgia. Published Online: July 13, 2009.
59. Solomon RL,. The opponent process theory of aquired motivation: The cost of pleasure and the benefits of pain. Am Psychol. 1980; 35: 691-712.
60. Peres MF, Mercante JP, Guendler VZ, et al. Cephalalgiaphobia: A possible specific phobia of illness. J Headache Pain. 2007; 8: 56-59.
61. Radat F, Lantéri-Minet M, Nachit-Ouinekh F, et al. The GRIM2005 study of migraine consultation in France. III: Psychological features of subjects with migraine. Cephalalgia. 2009; 29: 338-350.
62. Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: Results from the 10-year follow-up of the National Comorbidity Survey. Addiction. 2010; 105: 1117-1128.
63. Lake AE,. Medication overuse headache: Biobehavioral issues and solutions. Headache. 2006; 46: S88-S97.
64. Lake AE 3rd, Saper JR, Hamel RL,. Comprehensive inpatient treatment of refractory chronic daily headache. Headache. 2009; 49: 555-562.
65. Beck A, Wright E, Neuman C, Liese BS,. Cognitive Therapy of Substance Abuse. New York: Guilford Press ED; 1993.
66. Hyman SE, Malenka RC,. Addiction and the brain: The neurobiology of compulsion and its persistence. Nat Rev Neurosci. 2001; 2: 695-703.
67. Nestler EJ,. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem. 2002; 78: 637-647.
68. Volkow ND, Fowler JS, Wang GJ,. The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies. Neuropharmacology. 2004; 47: 3-13.
69. London ED, Ernst M, Grant S, Bonson K, Weinstein A,. Orbitofrontal cortex and human drug abuse: Functional imaging. Cereb Cortex. 2000; 10: 334-342.
70. Dom G, Sabbe B, Hulstijn W, Van Den Brink W,. Substance use disorders and the orbitofrontal cortex: Systematic review of behavioural decision-making and neuroimaging studies. Br J Psychiatry. 2005; 187: 209-220.
71. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006; 129: 543-550.
72. Maldonado R, Valverde O, Berrendero F,. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006; 29: 225-232.
73. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007; 32: 1384-1390.
74. Cupini LM, Costa C, Sarchielli P, et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008; 30: 186-189.
75. Carr D, Kalivas PW,. Orexin: A gatekeeper of addiction. Nat Med. 2006; 12: 274-276.
76. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: Findings from cerebrospinal fluid. Cephalalgia. 2008; 28: 714-722.
77. Nestler EJ,. Genes and addiction. Nat Genet. 2000; 26: 277-281.
78. Comings DE, Gonzalez N, Wu S, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999; 88: 358-368.
79. Shao C, Li Y, Jiang K, et al. Dopamine D4 receptor polymorphism modulates cue-elicited heroin craving in Chinese. Psychopharmacology (Berl). 2006; 186: 185-190.
80. Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006; 13: 1009-1013.
81. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG,. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996; 379: 606-612.
82. Di Lorenzo C, Sances G, Di Lorenzo G, et al. The wolframin His611Arg polymorphism influences medication overuse headache. Neurosci Lett. 2007; 424: 179-184.
83. Saper JR, Lake AE III,. Medication overuse headache: Type I and type II. Cephalalgia. 2006; 26: 1262.
84. Prochaska JO, DiClemente CC,. Stages of change in the modification of problem behaviors. Prog Behav Modif. 1992; 28: 183-218.
85. Nicholson RA,. Chronic headache: The role of the psychologist. Curr Pain Headache Rep. 2010; 14: 47-54.